Preliminary results from a phase 1/2 trial involving 1077 healthy adults found that vaccine induced strong antibody & T cell immune responses up to day 56 of the ongoing trial. These responses may be even greater after a 2nd dose, according to a sub-group study of 10 participants

— The Lancet (@TheLancet) July 20, 2020